Shanxi C&Y Pharmaceutical Group Co Ltd (300254) — Net Asset Quality Index
Shanxi C&Y Pharmaceutical Group Co Ltd (300254) has a Net Asset Quality Index of 37.2% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥1.55 Billion minus total liabilities of CN¥972.67 Million yields net assets of CN¥577.09 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check financial resilience of Shanxi C&Y Pharmaceutical Group Co Ltd to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Shanxi C&Y Pharmaceutical Group Co Ltd Net Asset Quality Index Over Time (2008–2024)
This chart shows how Shanxi C&Y Pharmaceutical Group Co Ltd's Net Asset Quality Index has evolved across 17 annual periods from 2008 to 2024. As of September 2025, the index stands at 37.2%, representing net assets of CN¥577.09 Million against total assets of CN¥1.55 Billion CNY. See Shanxi C&Y Pharmaceutical Group Co Ltd current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Shanxi C&Y Pharmaceutical Group Co Ltd (2008–2024)
The table below presents the year-by-year Net Asset Quality Index for Shanxi C&Y Pharmaceutical Group Co Ltd from 2008 to 2024, covering 17 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see market cap of Shanxi C&Y Pharmaceutical Group Co Ltd.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 38.6% | CN¥598.18 Million | CN¥1.55 Billion | CN¥949.55 Million | ▼ -15.7 pp |
| 2023 | 54.3% | CN¥778.43 Million | CN¥1.43 Billion | CN¥654.64 Million | ▲ +8.3 pp |
| 2022 | 46.1% | CN¥729.68 Million | CN¥1.58 Billion | CN¥854.64 Million | ▼ -2.7 pp |
| 2021 | 48.8% | CN¥744.58 Million | CN¥1.53 Billion | CN¥782.23 Million | ▲ +0.3 pp |
| 2020 | 48.5% | CN¥872.61 Million | CN¥1.80 Billion | CN¥927.91 Million | ▼ -3.3 pp |
| 2019 | 51.8% | CN¥932.60 Million | CN¥1.80 Billion | CN¥869.43 Million | ▼ -10.5 pp |
| 2018 | 62.3% | CN¥931.24 Million | CN¥1.50 Billion | CN¥564.47 Million | ▼ -1.7 pp |
| 2017 | 64.0% | CN¥971.17 Million | CN¥1.52 Billion | CN¥547.42 Million | ▼ -2.7 pp |
| 2016 | 66.7% | CN¥954.85 Million | CN¥1.43 Billion | CN¥477.74 Million | ▼ 0.0 pp |
| 2015 | 66.7% | CN¥872.50 Million | CN¥1.31 Billion | CN¥435.93 Million | ▼ -3.0 pp |
| 2014 | 69.7% | CN¥823.16 Million | CN¥1.18 Billion | CN¥358.17 Million | ▼ -0.7 pp |
| 2013 | 70.4% | CN¥767.16 Million | CN¥1.09 Billion | CN¥323.21 Million | ▼ -8.4 pp |
| 2012 | 78.7% | CN¥651.17 Million | CN¥827.16 Million | CN¥175.99 Million | ▼ -4.0 pp |
| 2011 | 82.7% | CN¥581.17 Million | CN¥702.56 Million | CN¥121.39 Million | ▲ +29.5 pp |
| 2010 | 53.3% | CN¥149.59 Million | CN¥280.84 Million | CN¥131.25 Million | ▲ +7.9 pp |
| 2009 | 45.3% | CN¥117.60 Million | CN¥259.51 Million | CN¥141.91 Million | ▼ -2.3 pp |
| 2008 | 47.6% | CN¥106.70 Million | CN¥224.15 Million | CN¥117.45 Million | — |